QQQ   292.99 (+0.94%)
AAPL   143.22 (+0.15%)
MSFT   245.25 (+1.05%)
META   148.05 (+0.67%)
GOOGL   97.63 (+0.71%)
AMZN   103.00 (+2.44%)
TSLA   171.76 (+3.06%)
NVDA   196.14 (+2.36%)
NIO   12.20 (+1.50%)
BABA   111.21 (+0.01%)
AMD   74.19 (+2.40%)
T   20.21 (+0.25%)
MU   59.92 (-2.90%)
F   13.32 (+3.34%)
CGC   2.93 (+3.17%)
GE   80.73 (-0.12%)
DIS   108.14 (+0.51%)
AMC   5.14 (+2.59%)
PFE   43.47 (-0.18%)
PYPL   80.67 (+1.29%)
NFLX   353.51 (+0.11%)
QQQ   292.99 (+0.94%)
AAPL   143.22 (+0.15%)
MSFT   245.25 (+1.05%)
META   148.05 (+0.67%)
GOOGL   97.63 (+0.71%)
AMZN   103.00 (+2.44%)
TSLA   171.76 (+3.06%)
NVDA   196.14 (+2.36%)
NIO   12.20 (+1.50%)
BABA   111.21 (+0.01%)
AMD   74.19 (+2.40%)
T   20.21 (+0.25%)
MU   59.92 (-2.90%)
F   13.32 (+3.34%)
CGC   2.93 (+3.17%)
GE   80.73 (-0.12%)
DIS   108.14 (+0.51%)
AMC   5.14 (+2.59%)
PFE   43.47 (-0.18%)
PYPL   80.67 (+1.29%)
NFLX   353.51 (+0.11%)
QQQ   292.99 (+0.94%)
AAPL   143.22 (+0.15%)
MSFT   245.25 (+1.05%)
META   148.05 (+0.67%)
GOOGL   97.63 (+0.71%)
AMZN   103.00 (+2.44%)
TSLA   171.76 (+3.06%)
NVDA   196.14 (+2.36%)
NIO   12.20 (+1.50%)
BABA   111.21 (+0.01%)
AMD   74.19 (+2.40%)
T   20.21 (+0.25%)
MU   59.92 (-2.90%)
F   13.32 (+3.34%)
CGC   2.93 (+3.17%)
GE   80.73 (-0.12%)
DIS   108.14 (+0.51%)
AMC   5.14 (+2.59%)
PFE   43.47 (-0.18%)
PYPL   80.67 (+1.29%)
NFLX   353.51 (+0.11%)
QQQ   292.99 (+0.94%)
AAPL   143.22 (+0.15%)
MSFT   245.25 (+1.05%)
META   148.05 (+0.67%)
GOOGL   97.63 (+0.71%)
AMZN   103.00 (+2.44%)
TSLA   171.76 (+3.06%)
NVDA   196.14 (+2.36%)
NIO   12.20 (+1.50%)
BABA   111.21 (+0.01%)
AMD   74.19 (+2.40%)
T   20.21 (+0.25%)
MU   59.92 (-2.90%)
F   13.32 (+3.34%)
CGC   2.93 (+3.17%)
GE   80.73 (-0.12%)
DIS   108.14 (+0.51%)
AMC   5.14 (+2.59%)
PFE   43.47 (-0.18%)
PYPL   80.67 (+1.29%)
NFLX   353.51 (+0.11%)
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$74.48
+1.17 (+1.60%)
(As of 01/31/2023 11:12 AM ET)
Add
Compare
Today's Range
$72.41
$74.74
50-Day Range
$56.22
$79.72
52-Week Range
$20.63
$82.00
Volume
242,161 shs
Average Volume
956,758 shs
Market Capitalization
$3.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$107.69

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
46.2% Upside
$108.15 Price Target
Short Interest
Bearish
22.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.14mentions of Axsome Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.43) to ($3.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

227th out of 1,055 stocks

Pharmaceutical Preparations Industry

108th out of 518 stocks


AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
AXSM April 21st Options Begin Trading
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
2 Promising New Growth Stocks to Watch in 2023
AXSM Axsome Therapeutics, Inc.
2 Stocks That Could Double Your Money in 2023
Got $5,000? 2 Unstoppable Stocks to Buy and Hold
TG Therapeutics: Would Santa Deliver An Early Present?
Axsome Therapeutics Stock: Bear vs. Bull
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
11/07/2022
Today
1/31/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$108.15
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+44.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-130,400,000.00
Pretax Margin
-622.89%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
32,135,000
Market Cap
$3.23 billion
Optionable
Optionable
Beta
1.83

Key Executives

  • Herriott Tabuteau
    Chairman & Chief Executive Officer
  • Mark L. Jacobson
    Chief Operating Officer
  • Nick PizzieNick Pizzie
    Chief Financial Officer
  • Joseph Debrah-Afful
    Controller
  • Amanda Jones
    Senior Vice President-Clinical Development













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

12 Wall Street analysts have issued 12 month target prices for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $75.00 to $210.00. On average, they expect the company's stock price to reach $108.15 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM stock has decreased by 3.4% and is now trading at $74.48.
View the best growth stocks for 2023 here
.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 7,940,000 shares, an increase of 5.2% from the December 31st total of 7,550,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 5.9 days. Currently, 22.4% of the shares of the company are short sold.
View Axsome Therapeutics' Short Interest
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings data on Monday, November, 7th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.07. The firm earned $16.85 million during the quarter, compared to the consensus estimate of $16.59 million.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.21%), Lindbrook Capital LLC (0.19%), Moody Aldrich Partners LLC (0.12%), Baldwin Brothers LLC MA (0.11%) and New York State Common Retirement Fund (0.07%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $74.48.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.23 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 1/31/2023 by MarketBeat.com Staff